LINK TO EVALUATION >> (opened after session) |
PARKING REQUEST FORM » | MAP & DIRECTIONS » |
ARB 304
|
ARB 305
|
ARB 354
|
ARB 355
|
|
Link to Teams Meeting
|
||||
Links to Handouts
|
|
|||
SESSION 1
1:00 – 1:45
|
Caity Blankenship, PharmD
IDH and FLT3 Inhibitor Combinations in Elderly Patients with Newly Diagnosed AML
|
Alison Rydell, PharmD
Optimizing Treatment for Gram Negative Bacteremia
|
Lauren Dickman, PharmD
DAPT Management in Bleeding Events: To Continue or Not to Continue?
|
Miranda Norvell, PharmD
Novel Approaches for the Management of Nonalcoholic Steatohepatitis
|
1:45 – 1:55 pm
|
Travel Time to accommodate movement between rooms
|
|||
SESSION 2
1:55 – 2:40
|
Katelyn Kennedy, PharmD
Trilaciclib in Chemotherapy-Induced Myelosuppression
|
Jesus Escamilla, PharmD
Updates on Inhaled Antibiotics for Ventilator-Associated Bacterial Pneumonia
|
Caitlyn Patton, PharmD
Tenecteplase for the Treatment of Pulmonary Embolism
|
Farah Alhalabi, PharmD
The role of SGLT2 inhibitors in the treatment
of heart failure
|
2:40 – 2:50 pm
|
Travel Time to accommodate movement between rooms
|
|||
SESSION 3
2:50 – 3:35
|
Morgan Blair, PharmD
Emerging Pharmacologic Therapies for Treatment Resistant Depression
|
Jessica Hall, PharmD
DOACs in LVT: To Be or Not To Be
|
Lauren Busch, PharmD
Impede the Bleed: Tranexamic Acid for Surgical and Traumatic Bleeds
|
Madison Schmidt, PharmD
The Role of Dual Incretin Agonists in
the Management of Type 2 Diabetes
|
Click here for a printable copy of the schedule
Registration is free but is required in advance for the LIVE presentations. Due to limited space, only those participants who register for the LIVE session before 5:00 PM on Friday, December 9, 2022 will be able to request parking access on campus.
PARKING: To request parking, please first register for your desired LIVE sessions. Then, complete the Parking Request Form using the link above, or complete your parking request by clicking here>>>. If you do not request parking on our campus, or if you do not submit your request by the deadline, you will be re-directed upon arrival.
ATTENDANCE: All live participants will be required to sign in on the paper sheets, located within each room. Paper sign-in sheets will be reconciled against completed evaluations. Attendance for the virtual sessions will be captured once a participant joins the session and will be reconciled with completed evaluations. Any sessions that you did not attend will be removed from your account within two weeks following the seminars.
CPE CREDIT: Immediately following Resident Seminar, participants should complete an evaluation for EACH presentation attended (3 maximum) by clicking here>>>. The evaluation link will open immediately following Resident Seminar. Participants will have one week after attending the session to complete the evaluation. The CPE Administrator will submit each participant’s NABP number and date of birth combination to CPE Monitor for continuing education credit, no later than two weeks after the live and virtual presentations. Only ONE session may be claimed for each of the three blocks. If multiple concurrent sessions are claimed, or if a session is claimed that is not reflected on the paper sign or the attendance roster within Microsoft Teams Meeting, the offending participant forfeits CE credit.
SPECIAL ACCOMMODATIONS
Attendees of all abilities are welcome to participate. If you require reasonable accommodations, please notify the CE Administrator via email at ce@uhsp.edu in advance so that she may secure resources as soon as possible. Every effort will be made to make accommodations where necessary.
Date: Dec 15, 2022 01:00 AM - 03:35 AM
Fee
CE Hours
Activity Type
- Knowledge
Objectives
- Identify the role in therapy of IDH1, IDH2, and FLT3 inhibitor targeted therapy in newly diagnosed elderly AML patients
- Evaluate the safety and efficacy of low intensity combination regimens for IDH1, IDH2, and FLT3 mutations in newly diagnosed elderly AML patients
Speaker(s)/Author(s)
Caity Blankenship, PharmD |
Activity Number
0033-0000-22-048-L01-PCE Hours
Location
Objectives
- Identify the most common causative organisms of Gram-negative bacteremia and current guideline recommendations
- Describe appropriate oral therapies for Gram-negative bacteremia
- Evaluate when it may be appropriate to transition from IV to oral therapies
Speaker(s)/Author(s)
Alison Rydell, PharmD |
Activity Number
0033-0000-22-046-L01-PCE Hours
Location
Objectives
- Describe the role and purpose for the use of DAPT
- Identify patients who are candidates for shortened durations of DAPT
- Discuss the reasoning and selection of monotherapy in select patients previously on DAPT
- Identify patients on DAPT who are candidates for the addition of PPI therapy
Speaker(s)/Author(s)
Lauren Dickman, PharmD |
Activity Number
0033-0000-22-042-L01-PCE Hours
Location
Objectives
- Identify the risk factors associated with nonalcoholic steatohepatitis
- Describe the mechanism of novel antidiabetic agents in relation to the pathophysiology of nonalcoholic steatohepatitis
- Select appropriate pharmacologic treatment options for patients with nonalcoholic steatohepatitis
Speaker(s)/Author(s)
Miranda Norvell, PharmD |
Activity Number
0033-0000-22-045-L01-PCE Hours
Location
Objectives
- Describe the mechanism of action by which trilaciclib prevents CIM in patients with small cell lung cancer
- Describe the conclusions of the three hallmark studies leading to the Food and Drug Administration's approval of Trilaciclib
- Identify the patient characteristics that would constitute trilaciclib as a favorable CIM treatment option
Speaker(s)/Author(s)
Katelyn Kennedy, PharmD |
Activity Number
0033-0000-22-052-L01-PCE Hours
Location
Objectives
- Discuss the current role of inhaled antibiotics in ventilator-associated pneumonia (VAP)
- Explain the potential benefit of inhaled aminoglycosides and colistin for the treatment of VAP
- Summarize the different clinical and microbiological outcomes presented in literature associated with inhaled aminoglycosides and colistin for the treatment of VAP to determine their role in therapy
Speaker(s)/Author(s)
Jesus Escamilla, PharmD |
Activity Number
0033-0000-22-043-L01-PCE Hours
Location
Objectives
- Describe the classifications of pulmonary embolism
- Compare and contrast studies investigating the efficacy and safety of tenecteplase for the treatment of pulmonary embolism
- Select an appropriate treatment for a patient presenting with pulmonary embolism
Speaker(s)/Author(s)
Caitlyn Patton, PharmD |
Activity Number
0033-0000-22-050-L01-PCE Hours
Location
Objectives
- Classify heart failure based on Left ventricular ejection fraction
- Compare the treatment recommendations between the 2017 and 2022 AHA/ACC/HFSA guideline
- Summarize the data supporting the use of SGLT2 inhibitors in patients with heart failure in the 2022 ACC/AHA heart failure guidelines
Speaker(s)/Author(s)
Farah Alhalabi, PharmD |
Activity Number
0033-0000-22-044-L01-PCE Hours
Location
Objectives
- Describe the presentation, incidence and treatment of unipolar depression
- Define Treatment Resistant Depression (TRD) and its impact on society
- Discuss existing and emerging pharmacological options for the treatment of TRD
Speaker(s)/Author(s)
Morgan Blair, PharmD |
Activity Number
0033-0000-22-049-L01-PCE Hours
Location
Objectives
- Identify risk factors for the development of left ventricular thrombus
- Summarize guideline recommendations for the treatment of left ventricular thrombus including the agent and duration of treatment
- Select an appropriate treatment regimen for left ventricular thrombus taking into consideration patient specific factors
Speaker(s)/Author(s)
Jessica Hall, PharmD |
Activity Number
0033-0000-22-047-L01-PCE Hours
Location
Objectives
- Describe the risks and benefits of tranexamic acid (TXA) use in trauma and surgical patients
- Explain the clinical controversies and unanswered questions behind the use of TXA
Speaker(s)/Author(s)
Lauren Busch, PharmD |
Activity Number
0033-0000-22-051-L01-PCE Hours
Location
Objectives
- Describe the incretin effect and identify the incretins involved
- Explain the mechanism of action of a dual incretin agonist
- Summarize the primary outcome and safety outcomes of the SURPASS-2 Trial
- Identify place in therapy of dual incretin agonists for patients with type 2 diabetes
Speaker(s)/Author(s)
Madison Schmidt, PharmD, MBA |